预约演示

Patients Taking Semaglutide See Benefit After Total Hip Replacement

2024-02-14

临床3期临床结果

Pictured: A packaged set of semaglutide injection pens/Peter Hansen for iStock The blockbuster weight-loss drug and diabetes treatment semaglutide has demonstrated some clinical benefit for patients receiving total hip replacements, according to study results unveiled Monday at the annual meeting of the American Academy of Orthopedic Surgeons (AAOS). According to one of the studies, semaglutide used before hip replacement showed “fewer prosthetic joint infections and readmissions.” The research led by Matthew Magruder, a third-year resident at Maimonides Health in Brooklyn, reported that patients taking the drug had some benefits—including lower rates of readmission within 90 days of surgery and lower rates of prosthetic joint infection. There were also no statistically significant higher rates of complications compared with controls, according to the announcement. Obesity and diabetes increases a patient risk of having a medical or surgical complication after joint replacement, such as wound healing problems and infection, AAOS noted. Another study investigated the postoperative complications of obese patients who used the drug and underwent the replacement compared to patients without any prior use of semaglutide who also had total hip arthroplasty (THA). Researchers found that the postoperative complications after the replacement are “similar” between obese patients using Novo Nordisk’s Wegovy compared to those who did not. Both groups had a parallel risk of several medical conditions such as hip arthroplasty revision, opioid-related disorders, prosthesis and surgical site infections, mortality, pulmonary embolism, deep vein thrombosis, shock and prosthesis dislocations, among other issues. The research was co-led by David Momtaz, a fourth-year medical student at the Long School of Medicine at UT Health San Antonio, and Daniel Pereira, an orthopedic surgery resident at Washington University Barnes-Jewish Hospital. AAOS did not provide raw data for either of these studies. Semaglutide is the active ingredient in Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Wegovy. While semaglutide has been seeing great success in weight management and diabetes, it is also looking to spread to other indications. In October 2023, Novo Nordisk ended a Phase III trial early after the study showed a high likelihood of success. The trial investigated semaglutide in the progression of renal impairment and the risk of renal and cardiovascular mortality in patients with chronic kidney disease. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构